Rifaximin for the Treatment of Irritable Bowel Syndrome
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
We have recently shown that the majority of patients with irritable bowel syndrome (IBS) have
an abnormal lactulose breath test to suggest the presence of bacterial overgrowth of the
small intestine. In open label and double blind treatment of IBS subjects with antibiotics, a
dramatic improvement in clinical symptoms are observed. In these studies, the antibiotic
chosen was neomycin, which is noted to have an efficacy of 20-25% in normalizing the
lactulose breath test. A more efficacious antibiotic is needed. Therefore the aim of this
study is to determine the efficacy of rifaximin in normalizing the lactulose breath test in
IBS subjects with concomitant improvement in clinical symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborators:
Bausch Health Americas, Inc. University of Chicago Valeant Pharmaceuticals International, Inc.